DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Aug 12

PMID 37568386

Authors

Tom Langenaeken

Arnaud Vanoppen

Fien Janssens

Loes Tanghe

Peter Verbrugghe

Filip Rega

Bart Meuris

Affiliations

Soon will be listed here.

Abstract

Evidence Acquisition: A literature search of Pubmed, Embase, Web of Science (Core Collection), and Cochrane Library (from inception to May 2023) was performed using a search string that was well defined and not modified during the study. An extensive overview of the search terms used in each database can be found in the Appendix. Only prospective clinical trials were included in this review. A total of 10 publications were included in this review.

Relevance To Clinical Practice: This systematic review summarizes the different types of DOACs and their possible use in the anticoagulation of mechanical valves. We aim to propose future directions in anticoagulation research for mechanical valves.

Conclusions: DOAC use in MHVs has been halted due to the failure of both dabigatran and apixaban in two major clinical trials. However, rivaroxaban was successful in two small clinical trials. Ample research is still needed to explore new valve designs as well as new anticoagulation targets.

Citing Articles

Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings.

Cohen O, Santagata D, Ageno W Haematologica. 2024; 109(10):3110-3124.

PMID: 38779744 PMC: 11443408. DOI: 10.3324/haematol.2023.283682.

Management and 1-Year Outcome in Elderly Patients with Hip Fracture Surgery Receiving Anticoagulation (Warfarin or DOAc) or P2Y12 Antiplatelet Agents.

Rostagno C, Rubbieri G, Zeppa M, Cartei A, Ceccofiglio A, Mannarino G J Clin Med. 2023; 12(19).

PMID: 37834822 PMC: 10573498. DOI: 10.3390/jcm12196178.

References

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

Schomburg J, Medina E, Lahti M, Bianco R . Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. J Invest Surg. 2012; 25(3):150-5. DOI: 10.3109/08941939.2011.616256. View

Scotten L, Siegel R . Importance of shear in prosthetic valve closure dynamics. J Heart Valve Dis. 2012; 20(6):664-72. View

McKellar S, Thompson 3rd J, Garcia-Rinaldi R, MacDonald R, Sundt 3rd T, Schaff H . Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine. J Thorac Cardiovasc Surg. 2008; 136(4):908-14. DOI: 10.1016/j.jtcvs.2008.01.045. View

Caldeira D, David C, Santos A, Costa J, Pinto F, Ferreira J . Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost. 2014; 12(5):650-9. DOI: 10.1111/jth.12544. View

Hylek E . Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med. 2004; 3(3):271-8. DOI: 10.1055/s-2003-44463. View

Van Hoof L, Truyers I, Van Hauwermeiren H, Nachtergaele B, Langenaeken T, Jacquemin M . Apixaban in a porcine model of mechanical valve thrombosis in pulmonary position-a pilot study. Interact Cardiovasc Thorac Surg. 2022; 35(2). PMC: 9297512. DOI: 10.1093/icvts/ivac070. View

Lester P, Coleman D, Diaz J, Jackson T, Hawley A, Mathues A . Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Arterioscler Thromb Vasc Biol. 2017; 37(5):942-948. DOI: 10.1161/ATVBAHA.116.308649. View

Wolberg A, Aleman M, Leiderman K, Machlus K . Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg. 2011; 114(2):275-85. PMC: 3264782. DOI: 10.1213/ANE.0b013e31823a088c. View

10.

Greiten L, McKellar S, Rysavy J, Schaff H . Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardiothorac Surg. 2013; 45(5):914-9. DOI: 10.1093/ejcts/ezt545. View

11.

Lau W, Torre C, Man K, Morgan Stewart H, Seager S, Van Zandt M . Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. Ann Intern Med. 2022; 175(11):1515-1524. DOI: 10.7326/M22-0511. View

12.

Jaffer I, Stafford A, Fredenburgh J, Whitlock R, Chan N, Weitz J . Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. J Am Heart Assoc. 2015; 4(8):e002322. PMC: 4599481. DOI: 10.1161/JAHA.115.002322. View

13.

Dangas G, Weitz J, Giustino G, Makkar R, Mehran R . Prosthetic Heart Valve Thrombosis. J Am Coll Cardiol. 2016; 68(24):2670-2689. DOI: 10.1016/j.jacc.2016.09.958. View

14.

Carrel T, Dembitsky W, de Mol B, Obrist D, Dreyfus G, Meuris B . Non-physiologic closing of bi-leaflet mechanical heart prostheses requires a new tri-leaflet valve design. Int J Cardiol. 2020; 304:125-127. DOI: 10.1016/j.ijcard.2020.01.056. View

15.

Mekaj Y, Mekaj A, Duci S, Miftari E . New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015; 11:967-77. PMC: 4485791. DOI: 10.2147/TCRM.S84210. View

16.

McKellar S, Abel S, Camp C, Suri R, Ereth M, Schaff H . Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011; 141(6):1410-6. DOI: 10.1016/j.jtcvs.2011.02.011. View

17.

Antonijevic N, Zivkovic I, Jovanovic L, Matic D, Kocica M, Mrdovic I . Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017; 18(7):622-635. DOI: 10.2174/1389200218666170427113504. View

18.

Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M . Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021; 18(12):853-864. DOI: 10.1038/s41569-021-00570-z. View

19.

Seiler C . Management and follow up of prosthetic heart valves. Heart. 2004; 90(7):818-24. PMC: 1768319. DOI: 10.1136/hrt.2003.025049. View

20.

Bruecker C, Li Q . Possible Early Generation of Physiological Helical Flow Could Benefit the Triflo Trileaflet Heart Valve Prosthesis Compared to Bileaflet Valves. Bioengineering (Basel). 2020; 7(4). PMC: 7763138. DOI: 10.3390/bioengineering7040158. View